Yu et al. demonstrated that KLF4 knockdown delayed tumor development and decreased pulmonary metastasis, while KLF4 expression levels served as a prognostic marker for stratifying HER2-enriched breast cancer according to distant metastasis-free survival [37, 57]. Here, ERBB2 is linked to breast cancer.